Acurx Pharmaceuticals, Inc. - Common Stock (ACXP)
0.7800
0.00 (0.00%)
Acurx Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel antimicrobial therapies to combat bacterial infections, particularly those caused by antibiotic-resistant pathogens
The company is engaged in research and development of innovative drug candidates that address critical unmet medical needs in the treatment of serious infections. With a commitment to advancing therapeutic options, Acurx aims to improve patient outcomes through its proprietary drug formulations and scientific expertise. The company's efforts are geared toward not only treating existing infections but also preventing the spread of multidrug-resistant bacteria in healthcare settings.
![](https://cdn.benzinga.com/files/images/story/2024/11/21/bitcoin-3024280.jpeg?width=1200&height=800&fit=crop)
As Bitcoin (CRYPTO: BTC) hit a new all-time high of $98,310 on Thursday morning during European trading hours, he total net asset value of U.S. Bitcoin spot exchange-traded funds (ETFs) has exceeded $100 billion, a milestone achieved in just 10 months since their
Via Benzinga · November 21, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ACXP stock results show that Acurx Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 9, 2024
![](https://cdn.benzinga.com/files/images/story/2024/07/18/Dominos-pizza.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · July 18, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 21, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ACXP stock results show that Acurx Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 15, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/18/image39.jpeg?width=1200&height=800&fit=crop)
Shares of Alcoa Corporation (NYSEAA) rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter.
Via Benzinga · April 18, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · March 19, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · March 19, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · March 18, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ACXP stock results show that Acurx Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 18, 2024
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • Niu Techs (NASDAQNIU) is expected to report earnings for its fourth quarter.
Via Benzinga · March 18, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/17/image24.jpeg?width=1200&height=800&fit=crop)
Shares of Airspan Networks Holdings Inc. (NASDAQMIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan Networks Holdings shares surged 381% to $0.3699 on Wednesday.
Via Benzinga · January 17, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 17, 2024
![](https://cdn.benzinga.com/files/images/story/2024/ACXP.png?width=1200&height=800&fit=crop)
Acurx Pharmaceuticals' ibezapolstat outperforms vancomycin with a 94% eradication rate. Stay tuned for Q1 2024 updates on Extended Clinical Cure and microbiome data.
Via Benzinga · January 17, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 17, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · December 14, 2023
![](https://cdn.benzinga.com/files/images/story/2023/12/11/acxp.png?width=1200&height=800&fit=crop)
Acurx Pharmaceuticals Inc (NASDAQACXP) released Phase 2b results showing 100% of C.
Via Benzinga · December 11, 2023
![](https://cdn.benzinga.com/files/images/story/2023/11/06/image14.jpg?width=1200&height=800&fit=crop)
Gainers Carbon Revolution Public Limited (NASDAQCREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp.
Via Benzinga · November 6, 2023
![](https://cdn.benzinga.com/files/images/story/2023/11/06/image42.jpg?width=1200&height=800&fit=crop)
Gainers Carbon Revolution Public Limited (NASDAQCREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp.
Via Benzinga · November 6, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 6, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 3, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 3, 2023